Fixing recalled breathing devices and winning permission to sell new ones are different finish lines.

The FDA's April 2024 announcement describes a consent decree requiring a remediation plan for affected patients, alongside restrictions on manufacturing and distribution subject to exceptions. Philips' own explanation says new U.S. CPAP and BiPAP sales cannot resume until relevant requirements are met. The research angle is the gap between servicing an installed patient base and returning to new sales. A count of repaired or replaced devices alone cannot establish regulatory clearance for new business. Conversely, sales restrictions do not mean all patient support has stopped.